Study Evaluating ReFacto in Hemophilia A
To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto® clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using two established hemophilia mutation testing laboratories (one in Europe and one in North America).
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Factor VIII Mutation Testing Program in Previously Untreated Patients (PUPs) With Hemophilia A Participating in ReFacto® Study|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00038909
|Study Director:||Medical Monitor, MD||Wyeth is now a wholly owned subsidiary of Pfizer|